← Back to headlines
Alnylam Targets 25% CAGR with Innovative Therapies
Alnylam Pharmaceuticals is targeting a 25% compound annual growth rate (CAGR) through its focus on innovative therapies.
26 Mar, 07:27 — 26 Mar, 07:27
Sources
Showing 1 of 1 sources
Related Stories
Critical Heat Measurements in Vienna Senior Apartments Prompt Calls for Subsidized Air Conditioning
21m ago
New Study Reveals High CTE Prevalence in Deceased NFL Players
33m ago
Latvian Government Increases Funding for Home Hospice Care
33m ago
Europe Records Over 35,000 Excess Deaths Due to Heatwaves
1h ago